Abstract
PKC isozymes have been put in place as oncoproteins since the discovery that they can function as receptors for potent tumor-promoting phorbol esters in the 1980s. Despite nearly two decades of research, a clear in vivo proof of that concept was missing. The availability of so-called knock out mouse lines of individual PKC genes provided a tool to investigate isozyme specific in vivo functions in the context of tumor initiation, development and progression. This review aims to provide a limited overview of how the application of these mouse lines in combination with a cancer mouse model helped to understand PKC's in vivo function during tumorigenesis. The focus of this review will be on skin, colon and lung cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
